Lucid Diagnostics (NASDAQ:LUCD) Price Target Raised to $7.50 at Ascendiant Capital Markets

Lucid Diagnostics (NASDAQ:LUCD) had its price objective upped by Ascendiant Capital Markets from $7.00 to $7.50 in a research report released on Monday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Several other equities analysts have also recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a report on Friday, April 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $2.00 price target on shares of Lucid Diagnostics in a report on Wednesday, March 26th. Finally, BTIG Research set a $2.00 price objective on Lucid Diagnostics in a research report on Tuesday, March 25th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $3.50.

Lucid Diagnostics Stock Performance

LUCD opened at $1.20 on Monday. The firm’s fifty day moving average is $1.42 and its two-hundred day moving average is $1.08. The firm has a market cap of $108.90 million, a PE ratio of -1.05 and a beta of 1.26. Lucid Diagnostics has a twelve month low of $0.63 and a twelve month high of $1.80.

Hedge Funds Weigh In On Lucid Diagnostics

Several hedge funds have recently modified their holdings of LUCD. Sargent Investment Group LLC bought a new position in Lucid Diagnostics in the fourth quarter valued at approximately $442,000. Citadel Advisors LLC acquired a new position in Lucid Diagnostics during the fourth quarter worth $98,000. Sunbelt Securities Inc. bought a new position in shares of Lucid Diagnostics in the 4th quarter valued at about $67,000. Geode Capital Management LLC lifted its stake in Lucid Diagnostics by 30.9% in the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock valued at $229,000 after purchasing an additional 65,964 shares during the last quarter. Finally, Lido Advisors LLC grew its holdings in Lucid Diagnostics by 40.0% during the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after purchasing an additional 40,000 shares during the period. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.